Overview of Radiologic Efficacy of New Treatments

Rheum Dis Clin North Am. 2004 May;30(2):285-93, vi. doi: 10.1016/j.rdc.2004.01.002.

Abstract

Randomized, double-blind trials on new treatments, including anakinra, etanercept, infliximab, and leflunomide, show convincing reduction in radiographic progression. The relative efficacy of these new treatments is unknown. Head-to-head comparisons have not been performed and comparing treatment arms across trials has several pitfalls. These possible pitfalls are discussed.

Publication types

  • Review

MeSH terms

  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / therapeutic use*
  • Arthritis, Rheumatoid / diagnostic imaging*
  • Arthritis, Rheumatoid / drug therapy*
  • Clinical Trials as Topic
  • Disease Progression
  • Etanercept
  • Humans
  • Immunoglobulin G / therapeutic use
  • Infliximab
  • Interleukin 1 Receptor Antagonist Protein
  • Isoxazoles / therapeutic use
  • Leflunomide
  • Radiography
  • Receptors, Tumor Necrosis Factor / therapeutic use
  • Severity of Illness Index
  • Sialoglycoproteins / therapeutic use
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • IL1RN protein, human
  • Immunoglobulin G
  • Interleukin 1 Receptor Antagonist Protein
  • Isoxazoles
  • Receptors, Tumor Necrosis Factor
  • Sialoglycoproteins
  • Infliximab
  • Leflunomide
  • Etanercept